{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T04:36:29Z","timestamp":1792125389046,"version":"4.4.0"},"reference-count":70,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100007102","name":"Zagazig University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007102","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic Chemistry"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.bioorg.2025.109009","type":"journal-article","created":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T02:15:39Z","timestamp":1758939339000},"page":"109009","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Antiplatelet therapy through inhibition of P2Y12 and phosphodiesterase receptors by novel synthesis 1,3-dicyclohexylpyrimidine-2,4(1H,3H)-dione derivatives with computational evaluation"],"prefix":"10.1016","volume":"165","author":[{"given":"Doaa A.","family":"Elsayed","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moustafa k.","family":"Soltan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mansoura Ali","family":"Abd-El-Maksoud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eman S.","family":"Tantawy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed F.","family":"El-Sayed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wesam S.","family":"Shehab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aamer","family":"Saeed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Basant","family":"Farag","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bioorg.2025.109009_bb0005","doi-asserted-by":"crossref","first-page":"e93","DOI":"10.1161\/CIR.0000000000001123","article-title":"Heart disease and stroke statistics\u20142023 update: a report from the American Heart Association","volume":"147","author":"Tsao","year":"2023","journal-title":"Circulation"},{"key":"10.1016\/j.bioorg.2025.109009_bb0010","doi-asserted-by":"crossref","first-page":"3317","DOI":"10.1016\/j.jtha.2023.09.013","article-title":"Antiplatelet strategies: past, present, and future","volume":"21","author":"Stanger","year":"2023","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.bioorg.2025.109009_bb0015","doi-asserted-by":"crossref","first-page":"2435","DOI":"10.1161\/STROKEAHA.120.028992","article-title":"Risk and secondary prevention of stroke recurrence: a population-base cohort study","volume":"51","author":"Flach","year":"2020","journal-title":"Stroke"},{"key":"10.1016\/j.bioorg.2025.109009_bb0020","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1161\/CIRCULATIONAHA.120.047065","article-title":"Trends in recurrent coronary heart disease after myocardial infarction among US women and men between 2008 and 2017","volume":"143","author":"Peters","year":"2021","journal-title":"Circulation"},{"key":"10.1016\/j.bioorg.2025.109009_bb0025","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1080\/17512433.2022.2121702","article-title":"Clinical pharmacology of antiplatelet drugs","volume":"15","author":"Gelbenegger","year":"2022","journal-title":"Expert. Rev. Clin. Pharmacol."},{"key":"10.1016\/j.bioorg.2025.109009_bb0030","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1186\/s40364-024-00700-y","article-title":"Platelet signaling in immune landscape: comprehensive mechanism and clinical therapy","volume":"12","author":"Yan","year":"2024","journal-title":"Biomark. Res."},{"key":"10.1016\/j.bioorg.2025.109009_bb0035","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1038\/s41569-021-00552-1","article-title":"Interplay between inflammation and thrombosis in cardiovascular pathology","volume":"18","author":"Stark","year":"2021","journal-title":"Nat. Rev. Cardiol."},{"key":"10.1016\/j.bioorg.2025.109009_bb0040","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1136\/bmj.296.6618.320","article-title":"Secondary prevention of vascular disease by prolonged antiplatelet treatment","volume":"296","year":"1988","journal-title":"Br. Med. J. (Clin. Res. Ed.)"},{"key":"10.1016\/j.bioorg.2025.109009_bb0045","doi-asserted-by":"crossref","first-page":"394","DOI":"10.7326\/0003-4819-129-5-199809010-00009","article-title":"The antiplatelet effects of ticlopidine and clopidogrel","volume":"129","author":"Sharis","year":"1998","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.bioorg.2025.109009_bb0050","series-title":"A Proposed Comprehensive Pathophysiology of Thrombotic Thrombocytopenic Purpura with Implicit Novel Tests and Therapies, in: Seminars in Thrombosis and Hemostasis","first-page":"356","author":"Nalbandian","year":"1980"},{"key":"10.1016\/j.bioorg.2025.109009_bb0055","doi-asserted-by":"crossref","first-page":"80","DOI":"10.3109\/09537104.2013.867427","article-title":"Ticagrelor as an alternative in clopidogrel-associated neutropenia","volume":"26","author":"Shah","year":"2015","journal-title":"Platelets"},{"key":"10.1016\/j.bioorg.2025.109009_bb0060","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1038\/s41569-023-00854-6","article-title":"Current concepts and novel targets for antiplatelet therapy","volume":"20","author":"Gawaz","year":"2023","journal-title":"Nat. Rev. Cardiol."},{"key":"10.1016\/j.bioorg.2025.109009_bb0065","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1002\/cpt.2526","article-title":"Clinical pharmacogenetics implementation consortium guideline for CYP2C19 genotype and clopidogrel therapy: 2022 update","volume":"112","author":"Lee","year":"2022","journal-title":"Clin. Pharmacol. Ther. (St. Louis, MO, U. S.)"},{"key":"10.1016\/j.bioorg.2025.109009_bb0070","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.119.014457","article-title":"Efficacy and safety of high potent P2Y12 inhibitors Prasugrel and Ticagrelor in patients with coronary heart disease treated with dual antiplatelet therapy: a sex-specific systematic review and meta-analysis","volume":"9","author":"Schreuder","year":"2020","journal-title":"J. Am. Heart Assoc."},{"key":"10.1016\/j.bioorg.2025.109009_bb0075","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1517\/17425255.2010.519334","article-title":"A comparison of the metabolism of clopidogrel and prasugrel","volume":"6","author":"Laizure","year":"2010","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"10.1016\/j.bioorg.2025.109009_bb0080","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1345\/aph.1M548","article-title":"Efficacy and safety of ticagrelor: a reversible P2Y12 receptor antagonist","volume":"44","author":"Anderson","year":"2010","journal-title":"Ann. Pharmacother."},{"key":"10.1016\/j.bioorg.2025.109009_bb0085","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1056\/NEJMoa0808227","article-title":"Genetic determinants of response to clopidogrel and cardiovascular events","volume":"360","author":"Simon","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bioorg.2025.109009_bb0090","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1056\/NEJMoa0809171","article-title":"Cytochrome p-450 polymorphisms and response to clopidogrel","volume":"360","author":"Mega","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bioorg.2025.109009_bb0095","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1001\/jama.2009.1232","article-title":"Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy","volume":"302","author":"Shuldiner","year":"2009","journal-title":"Jama"},{"key":"10.1016\/j.bioorg.2025.109009_bb0100","doi-asserted-by":"crossref","first-page":"4537","DOI":"10.2174\/1381612822666160617125308","article-title":"Novel anti-platelets in stable coronary artery disease","volume":"22","author":"Papageorgiou","year":"2016","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.bioorg.2025.109009_bb0105","doi-asserted-by":"crossref","first-page":"651","DOI":"10.3390\/catal9080651","article-title":"Assessment of ag nanoparticles interaction over low-cost mesoporous silica in deep desulfurization of diesel","volume":"9","author":"Sales","year":"2019","journal-title":"Catalysts"},{"key":"10.1016\/j.bioorg.2025.109009_bb0110","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1111\/j.1527-3466.2007.00027.x","article-title":"Prasugrel: a novel thienopyridine antiplatelet agent a review of preclinical and clinical studies and the mechanistic basis for its distinct antiplatelet profile","volume":"25","author":"Jakubowski","year":"2007","journal-title":"Cardiovascular Drug Reviews"},{"key":"10.1016\/j.bioorg.2025.109009_bb0115","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1111\/j.1365-2125.2011.04034.x","article-title":"Anti-platelet therapy: phosphodiesterase inhibitors","volume":"72","author":"Gresele","year":"2011","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.bioorg.2025.109009_bb0120","series-title":"PDE2 Structure and Functions, in: Cyclic Nucleotide Phosphodiesterases in Health and Disease","first-page":"55","author":"Martinez","year":"2006"},{"key":"10.1016\/j.bioorg.2025.109009_bb0125","series-title":"PDE3A Signalling in Blood Platelets","author":"Law","year":"2016"},{"key":"10.1016\/j.bioorg.2025.109009_bb0130","doi-asserted-by":"crossref","first-page":"2465","DOI":"10.1111\/jth.15844","article-title":"The NO\/cGMP\/PKG pathway in platelets: the therapeutic potential of PDE5 inhibitors in platelet disorders","volume":"20","author":"Degjoni","year":"2022","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.bioorg.2025.109009_bb0135","doi-asserted-by":"crossref","first-page":"2374","DOI":"10.1161\/STROKEAHA.120.029454","article-title":"Cilostazol for secondary prevention of stroke and cognitive decline: systematic review and meta-analysis","volume":"51","author":"McHutchison","year":"2020","journal-title":"Stroke"},{"issue":"2021","key":"10.1016\/j.bioorg.2025.109009_bb0140","first-page":"e364","article-title":"Guideline for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline from the American Heart Association\/American Stroke Association","volume":"52","author":"Kleindorfer","year":"2021","journal-title":"Stroke"},{"key":"10.1016\/j.bioorg.2025.109009_bb0145","first-page":"435","article-title":"Erectile dysfunction: comparison of efficacy and side effects of the PDE-5 inhibitors sildenafil, vardenafil and tadalafil-review of the literature","volume":"7","author":"Gresser","year":"2002","journal-title":"Eur. J. Med. Res."},{"key":"10.1016\/j.bioorg.2025.109009_bb0150","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1177\/0003319710362977","article-title":"Effects of tadalafil on platelets and endothelium in patients with erectile dysfunction and cardiovascular risk factors: a pilot study","volume":"61","author":"de Bon","year":"2010","journal-title":"Angiology"},{"key":"10.1016\/j.bioorg.2025.109009_bb0155","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0002-9149(99)00042-9","article-title":"Tissue distribution of phosphodiesterase families and the effects of sildenafil on tissue cyclic nucleotides, platelet function, and the contractile responses of trabeculae carneae and aortic rings in vitro","volume":"83","author":"Wallis","year":"1999","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.bioorg.2025.109009_bb0160","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1097\/00005344-200104000-00008","article-title":"Modulation of human platelet aggregation by the phosphodiesterase type 5 inhibitor sildenafil","volume":"37","author":"Berkels","year":"2001","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"10.1016\/j.bioorg.2025.109009_bb0165","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1080\/17425255.2018.1428557","article-title":"P2Y12 receptor inhibitors: an evolution in drug design to prevent arterial thrombosis","volume":"14","author":"Kupka","year":"2018","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"10.1016\/j.bioorg.2025.109009_bb0170","first-page":"4871","article-title":"Bleeding risk and the management of bleeding complications in patients undergoing anticoagulant therapy: focus on new anticoagulant agents, blood","volume":"111","author":"Crowther","year":"2008","journal-title":"J. Am. Soc. Hemat."},{"key":"10.1016\/j.bioorg.2025.109009_bb0175","doi-asserted-by":"crossref","DOI":"10.1002\/slct.202103834","article-title":"Synthesis, molecular docking and anticancer activity of some 5-aryl-5,10-dihydropyrido[2,3-d:6,5-d\u2019]dipyrimidine-2,4,6,8-tetraone derivatives and pyrido[2,3-d]pyrimidines","volume":"7","author":"Farag","year":"2022","journal-title":"ChemistrySelect"},{"key":"10.1016\/j.bioorg.2025.109009_bb0180","doi-asserted-by":"crossref","DOI":"10.1016\/j.molstruc.2025.142968","article-title":"Synthesis of Bis-Pyrimidothiazine and Bis-Pyrimidothiadiazinone derivatives as VEGFR2\/KDR inhibitors via Michael and Mannich reactions","author":"Badrey","year":"2025","journal-title":"J. Mol. Struct."},{"key":"10.1016\/j.bioorg.2025.109009_bb0185","doi-asserted-by":"crossref","first-page":"15436","DOI":"10.1038\/s41598-024-65166-2","article-title":"Pharmacokinetic and molecular docking studies to pyrimidine drug using Mn3O4 nanoparticles to explore potential anti-Alzheimer activity","volume":"14","author":"Shehab","year":"2024","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bioorg.2025.109009_bb0190","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1289\/ehp.11077","article-title":"Computational molecular modeling for evaluating the toxicity of environmental chemicals: prioritizing bioassay requirements","volume":"116","author":"Rabinowitz","year":"2008","journal-title":"Environ. Health Perspect."},{"key":"10.1016\/j.bioorg.2025.109009_bb0195","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1055\/s-0043-1775424","article-title":"Synthesis, in vitro and in silico molecular docking studies of novel phthalimide\u2013pyrimidine hybrid analogues to thalidomide as potent antitubercular agents","volume":"9","author":"Shehta","year":"2025","journal-title":"SynOpen"},{"key":"10.1016\/j.bioorg.2025.109009_bb0200","doi-asserted-by":"crossref","first-page":"8251","DOI":"10.1016\/S0040-4039(99)01751-7","article-title":"A convenient transformation of N-substituted ureas into N-(t-butoxycarbonyl) amines using a copper (II) salt-lithium t-butoxide system","volume":"40","author":"Yamaguchi","year":"1999","journal-title":"Tetrahedron Lett."},{"key":"10.1016\/j.bioorg.2025.109009_bb0205","doi-asserted-by":"crossref","DOI":"10.1002\/slct.202202534","article-title":"Design, synthesis, docking, 2D-QSAR modelling, anticancer and antioxidant evaluation of some new Azo-compounds derivatives and investigation of their fluorescence properties","volume":"7","author":"Hamed","year":"2022","journal-title":"ChemistrySelect"},{"key":"10.1016\/j.bioorg.2025.109009_bb0210","doi-asserted-by":"crossref","DOI":"10.1016\/j.molstruc.2024.140081","article-title":"Synthesis, structural, DFT studies, biological effectiveness, and molecular docking aspects of multitarget novel N-(4-Phenylthiazol-2-yl)hydrazine carboxamide hybrids as COX inhibitors, anti-TB, and anti-oxidant activity","volume":"1321","author":"Hiremath","year":"2025","journal-title":"J. Mol. Struct."},{"key":"10.1016\/j.bioorg.2025.109009_bb0215","doi-asserted-by":"crossref","DOI":"10.1016\/j.molstruc.2025.142163","article-title":"Design, synthesis and characterization of new fused pyrazole systems: In Vitro anti-bacterial, anti-fungal, antioxidant evaluation, In Silico DFT and molecular docking studies","volume":"1337","author":"Shehab","year":"2025","journal-title":"J. Mol. Struct."},{"key":"10.1016\/j.bioorg.2025.109009_bb0220","doi-asserted-by":"crossref","DOI":"10.1016\/j.molstruc.2021.131585","article-title":"Synthesis, crystal structure, hirshfeld surface analysis, spectral and quantum chemical studies of pharmaceutical cocrystals of a bronchodilator drug (theophylline)","volume":"1249","author":"Novena","year":"2022","journal-title":"J. Mol. Struct."},{"key":"10.1016\/j.bioorg.2025.109009_bb0225","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.molstruc.2015.03.049","article-title":"Spectroscopic investigations, NBO, HOMO\u2013LUMO, NLO analysis and molecular docking of 5-(adamantan-1-yl)-3-anilinomethyl-2,3-dihydro-1,3,4-oxadiazole-2-thione, a potential bioactive agent","volume":"1096","author":"Al-Omary","year":"2015","journal-title":"J. Mol. Struct."},{"key":"10.1016\/j.bioorg.2025.109009_bb0230","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113339","article-title":"Synthesis, biological evaluation, and docking studies of novel pyrrolo[2,3-b]pyridine derivatives as both ectonucleotide pyrophosphatase\/phosphodiesterase inhibitors and antiproliferative agents","volume":"217","author":"Ullah","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.109009_bb0235","doi-asserted-by":"crossref","DOI":"10.1016\/j.molstruc.2025.142280","article-title":"Harnessing the therapeutic potential of macromolecular metal (II) complexes derived from quinoline and thiazole core ligands: synthesis, spectral analysis, in vitro and in silico biological evaluation","volume":"1338","author":"Yernale","year":"2025","journal-title":"J. Mol. Struct."},{"key":"10.1016\/j.bioorg.2025.109009_bb0240","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.pharmthera.2014.10.003","article-title":"PDE5 inhibitors as therapeutics for heart disease, diabetes and cancer","volume":"147","author":"Das","year":"2015","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.bioorg.2025.109009_bb0245","doi-asserted-by":"crossref","first-page":"19969","DOI":"10.1074\/jbc.M603374200","article-title":"Characterization of the tandem GAF domain of human phosphodiesterase 5 using a cyanobacterial adenylyl cyclase as a reporter enzyme","volume":"281","author":"Bruder","year":"2006","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bioorg.2025.109009_bb0250","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1210\/en.2006-1079","article-title":"Characterization and functional role of androgen-dependent PDE5 activity in the bladder","volume":"148","author":"Filippi","year":"2007","journal-title":"Endocrinology"},{"key":"10.1016\/j.bioorg.2025.109009_bb0255","article-title":"The effect of clopidogrel and ticagrelor on human adipose mesenchymal stem cell osteogenic differentiation potential: in vitro comparative study","volume":"2024","author":"Mohamed","year":"2024","journal-title":"Adv. Pharma. Pharma. Sci."},{"key":"10.1016\/j.bioorg.2025.109009_bb0260","doi-asserted-by":"crossref","DOI":"10.1002\/slct.202404925","article-title":"Exploration of 1,3,4-oxadiazoles engrafted with indole and Phthalimide scaffolds as multi target peroxidase, acetylcholinesterase, and Butyrylchloinesterase inhibitors: synthesis, DFT calculations, and molecular docking studies","volume":"10","author":"Jaishree","year":"2025","journal-title":"ChemistrySelect"},{"key":"10.1016\/j.bioorg.2025.109009_bb0265","doi-asserted-by":"crossref","first-page":"S153","DOI":"10.56499\/jppres25.2327_13.s1.153","article-title":"Natural P2Y12 inhibitors as antiplatelet leads: a multi-tool in silico study","volume":"13","author":"Alzain","year":"2025","journal-title":"J. Pharma. Pharma. Res."},{"key":"10.1016\/j.bioorg.2025.109009_bb0270","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1080\/14786419.2019.1614582","article-title":"Discovery of two novel hetero-tricyclic lead scaffolds as PDE5A inhibitor: virtual screening, molecular docking and pharmacophore modeling approach","volume":"35","author":"Mali","year":"2021","journal-title":"Nat. Prod. Res."},{"key":"10.1016\/j.bioorg.2025.109009_bb0275","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1007\/s13738-025-03179-y","article-title":"Exploration of novel isoniazid embedded 1,3,4-oxadiazole hybrids as anti-TB, antioxidant, and COX inhibitors: synthesis, spectral analysis, and molecular modeling studies","volume":"22","author":"Jisha","year":"2025","journal-title":"J. Iran. Chem. Soc."},{"key":"10.1016\/j.bioorg.2025.109009_bb0280","first-page":"33","article-title":"Open babel: an open chemical toolbox","volume":"3","author":"O\u2019Boyle","year":"2011","journal-title":"J. Chemother."},{"key":"10.1016\/j.bioorg.2025.109009_bb0285","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/s10822-016-0006-1","article-title":"DockingApp: a user friendly interface for facilitated docking simulations with AutoDock Vina","volume":"31","author":"Di Muzio","year":"2017","journal-title":"J. Comput. Aided Mol. Des."},{"key":"10.1016\/j.bioorg.2025.109009_bb0290","article-title":"Design, synthesis, and in vitro and in silico biological exploration of novel pyridine-embedded 1,3,4-Oxadiazole hybrids as potential antimicrobial agents","volume":"2025","author":"S. KN, B. SM, N. GY, P. K, Y. M, A. NR, O. HN","year":"2025","journal-title":"J. Chemother."},{"key":"10.1016\/j.bioorg.2025.109009_bb0295","series-title":"Discovery Studio Modeling Environment, in, Release San Diego, CA","author":"Biovia","year":"2017"},{"key":"10.1016\/j.bioorg.2025.109009_bb0300","article-title":"Next generation 3D pharmacophore modeling, Wiley interdisciplinary reviews: computational molecular","volume":"10","author":"Schaller","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.bioorg.2025.109009_bb0305","doi-asserted-by":"crossref","DOI":"10.1063\/5.0018516","article-title":"Heterogeneous parallelization and acceleration of molecular dynamics simulations in GROMACS","volume":"153","author":"P\u00e1ll","year":"2020","journal-title":"J. Chem. Phys."},{"key":"10.1016\/j.bioorg.2025.109009_bb0310","series-title":"P2Y12-Dependent Modulation of ADP-Evoked Calcium Responses in Human Monocytes, in","author":"Micklewright","year":"2018"},{"key":"10.1016\/j.bioorg.2025.109009_bb0315","doi-asserted-by":"crossref","first-page":"3784","DOI":"10.1021\/jm9003297","article-title":"High-affinity, non-nucleotide-derived competitive antagonists of platelet P2Y12 receptors","volume":"52","author":"Baqi","year":"2009","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.109009_bb0320","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1146\/annurev.immunol.26.021607.090331","article-title":"PD-1 and its ligands in tolerance and immunity","volume":"26","author":"Keir","year":"2008","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.bioorg.2025.109009_bb0325","doi-asserted-by":"crossref","first-page":"2554","DOI":"10.1111\/bph.14205","article-title":"PDE5 inhibitors\u2013pharmacology and clinical applications 20 years after sildenafil discovery","volume":"175","author":"Andersson","year":"2018","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.bioorg.2025.109009_bb0330","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1038\/sj.ijir.3900726","article-title":"The phosphodiesterase inhibitory selectivity and the in vitro and in vivo potency of the new PDE5 inhibitor vardenafil","volume":"13","author":"Saenz de Tejada","year":"2001","journal-title":"Int. J. Impot. Res."},{"key":"10.1016\/j.bioorg.2025.109009_bb0335","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1007\/s00249-021-01530-8","article-title":"A standard operating procedure for an enzymatic activity inhibition assay","volume":"50","author":"Smirnovien\u0117","year":"2021","journal-title":"Eur. Biophys. J."},{"key":"10.1016\/j.bioorg.2025.109009_bb0340","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1186\/1471-2164-9-516","article-title":"Establishing an adjusted p-value threshold to control the family-wide type 1 error in genome wide association studies","volume":"9","author":"Duggal","year":"2008","journal-title":"BMC Genomics"},{"key":"10.1016\/j.bioorg.2025.109009_bb0345","doi-asserted-by":"crossref","first-page":"331","DOI":"10.4097\/kja.d.18.00292","article-title":"More about the basic assumptions of t-test: normality and sample size","volume":"72","author":"Kim","year":"2019","journal-title":"Korean J. Anesthesiol."},{"key":"10.1016\/j.bioorg.2025.109009_bb0350","doi-asserted-by":"crossref","first-page":"89","DOI":"10.12997\/jla.2023.12.2.89","article-title":"Are only p-values less than 0.05 significant? A p-value greater than 0.05 is also significant!","volume":"12","author":"Kwak","year":"2023","journal-title":"J. Lipid Atherosclerosis"}],"container-title":["Bioorganic Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206825008892?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206825008892?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T20:37:57Z","timestamp":1760560677000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0045206825008892"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":70,"alternative-id":["S0045206825008892"],"URL":"https:\/\/doi.org\/10.1016\/j.bioorg.2025.109009","relation":{},"ISSN":["0045-2068"],"issn-type":[{"value":"0045-2068","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antiplatelet therapy through inhibition of P2Y12 and phosphodiesterase receptors by novel synthesis 1,3-dicyclohexylpyrimidine-2,4(1H,3H)-dione derivatives with computational evaluation","name":"articletitle","label":"Article Title"},{"value":"Bioorganic Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bioorg.2025.109009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"109009"}}